Pancreatic Cancer Treatment
~ Genetics of Breast & Ovarian Cancer

Treatment for HBOC- or BRCA1/2 mutation-related pancreatic cancer

List was last updated on Dec 9, 2019 @ 8:54 am.


    • Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    • Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0582-7. [Epub ahead of print]

    Editorial:

    Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.

    • Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.
    • Lowery MA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0645-9. [Epub ahead of print]
    • From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
    • Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I.
    • Nat Rev Clin Oncol. 2019 Nov 8. doi: 10.1038/s41571-019-0281-6. [Epub ahead of print]
    • Review
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    • Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N.
    • Medicine (Baltimore). 2019 Oct;98(40):e17443. doi: 10.1097/MD.0000000000017443.
    • Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    • Hammel P, Kindler HL, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T.
    • Ann Oncol. 2019 Sep 28. pii: mdz406. doi: 10.1093/annonc/mdz406. [Epub ahead of print]
    • Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    • Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N.
    • Cancer Treat Rev. 2019 Sep 6;80:101895. doi: 10.1016/j.ctrv.2019.101895. [Epub ahead of print]
    • Review
    • Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.
    • Elaileh A, Saharia A, Potter L, Baio F, Ghafel A, Abdelrahim M, Heyne K.
    • Am J Cancer Res. 2019 Sep 1;9(9):1871-1888. eCollection 2019.
    • Should PARP Inhibitors Have Tumor-Agnostic Approval Status?
    • Markman M.
    • Medscape Oncology. 2019 Aug 19.

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
    • Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G.
    • Oncologist. 2019 Aug 7. pii: theoncologist.2018-0905. doi: 10.1634/theoncologist.2018-0905. [Epub ahead of print]
    • Screening for Pancreatic Cancer.
    • Lucas AL, Kastrinos F.
    • JAMA. 2019 Aug 6;322(5):407-408. doi: 10.1001/jama.2019.9690.

    Guidelines:

    Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement.

    Editorial:

    Screening for Pancreatic Cancer Gets a D, But the Student Is Improving.

    Editorial:

    Screening for Pancreatic Cancer-Is There Hope?

    • Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
    • Furuse J.
    • J Clin Med. 2019 Aug 4;8(8). pii: E1170. doi: 10.3390/jcm8081170.
    • Maintenance Olaparib New Standard in Pancreatic Cancer?
    • [No authors listed]
    • Cancer Discov. 2019 Jun 4. doi: 10.1158/2159-8290.CD-NB2019-065. [Epub ahead of print]
    • Conference news
    • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
    • N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903387. [Epub ahead of print]

    Research news: Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations. (FORCE. XRAYS.)

    Research news: Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (GenomeWeb)

    Research news: Olaparib Delays Progression in BRCA Pancreatic Cancer. (Medscape Oncology)

    Commentary, Research news: Should PARP Inhibitors Have Tumor-Agnostic Approval Status? (Medscape Oncology)

    • Pancreatic cancer in young adults: changes, challenges, and solutions.
    • Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D.
    • Onco Targets Ther. 2019 May 6;12:3387-3400. doi: 10.2147/OTT.S176700. eCollection 2019.
    • Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis.
    • Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, Cabrera IF, Reques ED, Ielpo B, Glagolieva AY, Plaza C.
    • Ann Hepatobiliary Pancreat Surg. 2019 May;23(2):200-205. doi: 10.14701/ahbps.2019.23.2.200. Epub 2019 May 31.
    • Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
    • Kryklyva V, Haj Mohammad N, Morsink FHM, Ligtenberg MJL, Offerhaus GJA, Nagtegaal ID, de Leng WWJ, Brosens LAA.
    • Cancer Biol Ther. 2019 Apr 19:1-7. doi: 10.1080/15384047.2019.1595274. [Epub ahead of print]
    • Maintenance Rucaparib Controls Some Pancreatic Cancers.
    • [No authors listed]
    • Cancer Discov. 2019 Apr 2. doi: 10.1158/2159-8290.CD-NB2019-043. [Epub ahead of print]
    • PARP Inhibitors for Maintenance Therapy in Pancreatic Cancer?
    • Castellino AM.
    • Medscape. Medscape Oncology. 2019 Apr 2.

    Conference abstract: CT234 - A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 (AACR Annual Meeting 2019)

    • Familial Pancreatic Cancer and Surveillance of High-Risk Individuals.
    • Matsubayashi H, Takaori K, Morizane C, Kiyozumi Y.
    • Gut Liver. 2019 Mar 26. doi: 10.5009/gnl18449. [Epub ahead of print]
    • Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    • Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM.
    • Cancer Treat Rev. 2019 Mar 22;75:27-38. doi: 10.1016/j.ctrv.2019.03.003. [Epub ahead of print]
    • Review
    • Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    • Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.
    • Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.
    • Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies.
    • Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L.
    • Cancers (Basel). 2019 Feb 7;11(2). pii: E193. doi: 10.3390/cancers11020193.
    • Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Ohmoto A, Yachida S, Morizane C.
    • Int J Mol Sci. 2019 Jan 29;20(3). pii: E561. doi: 10.3390/ijms20030561.
    • Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.
    • Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.
    • Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
    • Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.
    • Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.
    • Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    • Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B.
    • Pharmacogenomics. 2019 Jan;20(2):113-127. doi: 10.2217/pgs-2018-0073. Epub 2018 Dec 12.
    • Review
    • Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    • Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH.
    • Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.
    • Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
    • Gleeson FC, Levy MJ.
    • Curr Treat Options Gastroenterol. 2018 Dec;16(4):441-448. doi: 10.1007/s11938-018-0195-x.
    • Review
    • Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
    • Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, Han X, Lang J, Qin H, Shi Q, Zhang Z, Tian X, Anderson GJ, Zhao Y, Nie G, Yang Y.
    • ACS Nano. 2018 Nov 27;12(11):10785-10796. doi: 10.1021/acsnano.8b01573. Epub 2018 Nov 12.
    • Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    • Li M, Mou Y, Hou S, Cao D, Li A.
    • Medicine (Baltimore). 2018 Nov;97(45):e13113. doi: 10.1097/MD.0000000000013113.
    • My Father’s Fight Against the Breast-Cancer Gene.
    • Munster P.
    • The Wall Street Journal. The Saturday Essay. 2018 Sep 28.

    Blog post: Pamela Munster's story: Cancer in the family (FORCE. XRAYS.)

    • Harnessing the Immune System in Pancreatic Cancer.
    • Das S, Berlin J, Cardin D.
    • Curr Treat Options Oncol. 2018 Aug 20;19(10):48. doi: 10.1007/s11864-018-0566-5.
    • Review
    • Emerging strategies in BRCA-positive pancreatic cancer.
    • Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D.
    • J Cancer Res Clin Oncol. 2018 Aug;144(8):1503-1507. doi: 10.1007/s00432-018-2666-9. Epub 2018 May 18.
    • Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    • Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R.
    • Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23.
    • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
    • Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.
    • Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.
    • Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
    • Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.
    • Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.
    • Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.
    • Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, Takaori K, Matsumoto S, Miyake H, Okuno Y, Muto M.
    • Oncotarget. 2018 Apr 13;9(28):19817-19825. doi: 10.18632/oncotarget.24865. eCollection 2018 Apr 13.
    • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
    • O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.
    • Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.
    • BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    • Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J.
    • J Am Coll Surg. 2018 Apr;226(4):630-637.e1. doi: 10.1016/j.jamcollsurg.2017.12.021. Epub 2018 Jan 5.
    • Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy.
    • Shahda S, Timms KM, Ibrahim AA, Reid JE, Cramer HM, Radovich M, Ibrahim S, Allen B, O’Neil BH
    • JCO Precis Oncol. doi: 10.1200/PO.17.00087. Epub 2017 Jan 19.

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations.
    • Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. doi: 10.1200/PO.17.00152. Epub 2018 Jan 19.

    Free full text: Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. (Medscape Oncology)

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    • Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.
    • Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
    • Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    • Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.
    • Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.
    • Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
    • Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.
    • Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
    • Schmitt A, Feldmann G, Zander T, Reinhardt HC.
    • Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.
    • Risk factors, biomarker and imaging techniques used for pancreatic cancer screening.
    • Thomas C.
    • Chin Clin Oncol. 2017 Dec;6(6):61. doi: 10.21037/cco.2017.12.06.
    • Familial Pancreatic Cancer and the Future of Directed Screening.
    • Welinsky S, Lucas AL.
    • Gut Liver. 2017 Nov 15;11(6):761-770. doi: 10.5009/gnl16414.
    • DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
    • Golan T, Javle M.
    • J Natl Compr Canc Netw. 2017 Aug;15(8):1063-1069. doi: 10.6004/jnccn.2017.0133.
    • Review
    • Olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer.
    • Yarchoan M, Myzak MC, Johnson Iii BA, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.
    • Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.
    • Hereditary pancreatic cancer: related syndromes and clinical perspective.
    • Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G.
    • Hered Cancer Clin Pract. 2017 Jun 28;15:9. doi: 10.1186/s13053-017-0069-6. eCollection 2017.
    • Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
    • Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.
    • Am Soc Clin Oncol Educ Book. [Presented Monday, June 5, 2017.] 2017;37:301-310. doi: 10.14694/EDBK_175222.
    • Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    • Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MH, Bavi P, Bartlett JM, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.
    • JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.
    • Verdaguer H, Saurí T, Macarulla T.
    • J Gastrointest Oncol. 2017 Jun;8(3):405-417. doi: 10.21037/jgo.2016.11.15.
    • BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.
    • Zhu Y, Zhai K, Ke J, Li J, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Gong J, Zhong R, Huang K, Chang J, Miao X.
    • Oncotarget. 2017 May 30;8(22):36033-36039. doi: 10.18632/oncotarget.16422.
    • Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
    • Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):301-310. doi: 10.1200/EDBK_175222.
    • Germline mutations in pancreatic cancer and potential new therapeutic options.
    • Pihlak R, Valle JW, McNamara MG.
    • Oncotarget. 2017 Apr 20;8(42):73240-73257. doi: 10.18632/oncotarget.17291. eCollection 2017 Sep 22.
    • BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    • Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.
    • Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.
    • Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    • Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.
    • Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.
    • Familial pancreatic cancer: Concept, management and issues.
    • Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T.
    • World J Gastroenterol. 2017 Feb 14;23(6):935-948. doi: 10.3748/wjg.v23.i6.935.
    • Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    • Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.
    • PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.
    • Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    • Lemstrova R, Melichar B, Mohelnikova-Duchonova B.
    • Cancer Chemother Pharmacol. 2016 Dec;78(6):1101-1111. Epub 2016 Jun 1.
    • Review
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    • de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.
    • Endocr Relat Cancer. 2016 Oct;23(10):T57-T67. Epub 2016 Aug 10.

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
    • Teo MY, O'Reilly EM.
    • J Gastrointest Oncol. 2016 Oct;7(5):738-749.
    • Insights on Hereditary Pancreatic Cancer.
    • Michael J Hall
    • FORCE. Be Empowered Webinars. 2016 Sep 6.
    • Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
    • Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH.
    • World J Gastroenterol. 2016 Aug 28;22(32):7275-88. doi: 10.3748/wjg.v22.i32.7275.
    • Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    • Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.
    • Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.
    • Review
    • Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    • Peters ML, Tseng JF, Miksad RA.
    • Clin Ther. 2016 Jul;38(7):1622-35. doi: 10.1016/j.clinthera.2016.03.006. Epub 2016 Apr 1.
    • Changing the course of pancreatic cancer - Focus on recent translational advances.
    • Javle M, Golan T, Maitra A.
    • Cancer Treat Rev. 2016 Mar;44:17-25. doi: 10.1016/j.ctrv.2016.01.004. Epub 2016 Jan 25.
    • Review
    • Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    • Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM.
    • Expert Opin Ther Targets. 2016 Mar;20(3):341-59. doi: 10.1517/14728222.2016.1094057. Epub 2015 Oct 6.
    • Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".
    • Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii.
    • Letter

    Case report

    Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

    Response / Letter

    The Authors Respond.

    • Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
    • Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T.
    • Med Oncol. 2016 Jan;33(1):4. doi: 10.1007/s12032-015-0720-x. Epub 2015 Dec 22.
    • The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
    • Martinez-Useros J, Garcia-Foncillas J.
    • Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18.
    • Diagnosis and Management of Hereditary Pancreatic Cancer.
    • Humphris JL, Biankin AV.
    • Recent Results Cancer Res. 2016;205:61-83. doi: 10.1007/978-3-319-29998-3_5.
    • Adenosquamous Carcinoma of the Pancreas in a Patient with BRCA2 Mutation: A Case Report.
    • Yeung V, Palmer JD, Williams N, Weinstein JC, Fortuna D, Sama A, Winter J, Bar-Ad V.
    • Case Rep Pancreat Cancer. 2015 Nov 1;1(1):22-25. doi: 10.1089/crpc.2015.29003.vye. eCollection 2015.
    • Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma.
    • Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M.
    • Case Rep Oncol. 2015 Oct 22;8(3):447-450. doi: 10.1159/000441414.
    • Pancreatic cancer: BRCA mutation and personalized treatment.
    • Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X.
    • Expert Rev Anticancer Ther. 2015 Oct;15(10):1223-31. doi: 10.1586/14737140.2015.1086271. Epub 2015 Sep 7.
    • Review
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
    • Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G.
    • Cancer Lett. 2015 Aug 1;364(1):8-16. doi: 10.1016/j.canlet.2015.04.003. Epub 2015 Apr 9.
    • BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
    • Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.
    • Br J Cancer. 2015 Jul 28;113(3):425-432. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.
    • Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.
    • Vyas O, Leung K, Ledbetter L, Kaley K, Rodriguez T, Garcon MC, Saif MW.
    • Anticancer Drugs. 2015 Feb;26(2):224-6. doi: 10.1097/CAD.0000000000000178.
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Comment / Letter

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter

    To BRCA or Not to PALB.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
    • Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S.
    • Br J Cancer. 2014 Sep 9;111(6):1132-1138. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.
    • PARP-Inhibitors in BRCA-Associated Pancreatic Cancer.
    • Bhalla A, Saif MW.
    • JOP. 2014 Jul 28;15(4):340-3. doi: 10.6092/1590-8577/2690.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • BRCA and Pancreatic Cancer.
    • Brennan GT, Relias V, Saif MW.
    • JOP. 2013 Jul 10;14(4):325-8. doi: 10.6092/1590-8577/1652.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
    • Partensky C.
    • Pancreas. 2013 Jul;42(5):729-39. doi: 10.1097/MPA.0b013e318288107a.
    • Review
    • PARP Inhibitors Hold Promise in Pancreas Cancer.
    • Eileen O'Reilly.
    • Medscape Medical News. Medscape Oncology. 2013 Annual Meeting of the American Society of Clinical Oncology. 2013 Jun 17.
    • Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
    • Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A.
    • Mol Oncol. 2013 Jun;7(3):308-22. doi: 10.1016/j.molonc.2012.10.002. Epub 2012 Oct 29.
    • BRCA-associated pancreatic cancer: the evolving management.
    • Leung K, Saif MW.
    • JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • BRCA and pancreatic cancer: selection of chemotherapy.
    • Kim R, Byer J, Saif MW.
    • JOP. 2012 Mar 10;13(2):180-1.